八羟基-4,7-亚甲基-1H-吲哚-5-醇 | 13380-89-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 八羟基-4,7-亚甲基-1H-吲哚-5-醇
• 中文别名: 八氢-4,7-甲桥-1H-茚-5-醇
• 英文名称: Hydroxy-tetrahydrodicyclopentadien
• 英文别名: exo-8-Hydroxy-exo-tricyclo<5.2.1.0^2,6>decan；tricyclo[5.2.1.02,6 ]decan-8-ol；tricyclo[5.2.1.02,6 ]deca-8-yl alcohol；Octahydro-4,7-methano-1H-inden-5-ol；tricyclo[5.2.1.02,6]decan-8-ol
• CAS: 13380-89-7
• 化学式: C₁₀H₁₆O
• mdl: MFCD00168035
• 分子量: 152.236
• InChiKey: FKZJBAXKHJIQDU-UHFFFAOYSA-N

物化性质

• 熔点：
  120-121 °C
• 沸点：
  255℃
• 密度：
  1.115
• 闪点：
  105℃
• LogP：
  2.479 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2906199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  八羟基-4,7-亚甲基-1H-吲哚-5-醇 以78的产率得到D609钾盐
  参考文献：
  名称：

  Xanthates as antitumor agents

  摘要：

  本发明揭示了一种新型的抗肿瘤和抗病毒黄酸盐化合物，以及制备它们的方法，包含该黄酸盐化合物的制药组合物，以及使用该黄酸盐化合物对抗病毒和肿瘤的方法。

  公开号：

  US04981869A1
• 作为产物：
  描述：

  三环癸-3-烯-8-醇 在 镍 氢气 作用下， 生成 八羟基-4,7-亚甲基-1H-吲哚-5-醇
  参考文献：
  名称：

  Kheifits,L.A.; Virezub,S.I., Journal of general chemistry of the USSR, 1964, vol. 34, p. 2093 - 2095

  摘要：

  DOI：

文献信息

• Aryl substituted nitrogen heterocyclic antidepressants
  申请人：Pfizer Inc.

  公开号：US05128358A1

  公开（公告）日：1992-07-07

  Antidepressant agents having the formula ##STR1## wherein R.sup.1 is a polycycloalkyl group; R.sup.2 is methyl or ethyl, X is O; and Y comprises a 5-membered heterocyclic ring having one or two nitrogens.

  具有以下结构式的抗抑郁药物代理：其中R.sup.1是多环脂肪烷基基团；R.sup.2是甲基或乙基，X是O；Y包括一个含有一个或两个氮原子的5元杂环环。
• Fluorine-Containing Sulfonic Acid Salt, Fluorine-Containing Sulfonic Acid Salt Resin, Resist Composition, and Pattern Forming Method Using Same
  申请人：Central Glass Company, Limited

  公开号：US20150198879A1

  公开（公告）日：2015-07-16

  Disclosed is a fluorine-containing sulfonic acid salt resin having a repeating unit represented by the following general formula (3). In the formula, each A independently represents a hydrogen atom, a fluorine atom or a trifluoromethyl group, and n represents an integer of 1-10. W represents a bivalent linking group, R 01 represents a hydrogen atom or a monovalent organic group, and M + represents a monovalent cation. A resist composition containing this resin is further superior in sensitivity, resolution and reproducibility of mask pattern and is capable of forming a pattern with a low LER.

  本公开了一种含氟磺酸盐树脂，其具有以下通用式（3）所代表的重复单元。在该式中，每个A独立地表示氢原子、氟原子或三氟甲基基团，n表示1-10的整数。W表示二价连接基团，R01表示氢原子或一价有机基团，M+表示一价阳离子。含有该树脂的抗蚀组合物在感光性、分辨率和掩膜图案的重现性方面更加优越，并且能够形成具有较低LER的图案。
• POLYMERIZABLE ESTER COMPOUND, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS
  申请人：HASEGAWA Koji

  公开号：US20130017484A1

  公开（公告）日：2013-01-17

  Polymerizable ester compounds having formula (1) are novel wherein R 1 is H, F, methyl or trifluoromethyl, R 2 is an acid labile group, Aa is a divalent hydrocarbon group which may be separated by —O— or —C(═O)—, and k 1 is 0 or 1. They are useful as monomers to produce polymers which are transparent to radiation ≦500 nm. Radiation-sensitive resist compositions comprising the polymers as base resin exhibit excellent developed properties.

  具有式（1）的可聚合酯化合物是新颖的，其中R1为H、F、甲基或三氟甲基，R2为酸敏感基团，Aa为二价的碳氢基团，可以通过—O—或—C（═O）—分离，k1为0或1。它们可用作单体，用于生产对辐射≦500 nm透明的聚合物。以这些聚合物作为基础树脂的辐射敏感抗蚀剂组合物表现出优异的显影性能。
• Substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and a medicament comprising them
  申请人：——

  公开号：US20010023257A1

  公开（公告）日：2001-09-20

  The application discloses substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics and a medicament comprising them Substituted norbornylamino derivatives having exo-configured nitrogen and an endo-fused five-membered ring of the formula I, or having exo-configured nitrogen and an exo-fused five-membered ring of the formula I a 1 in which R1, R2, R3, R4, R5, A, B, S1, and S2 are as defined in the claims, are highly suitable for use as antihypertensive agents, for reducing or preventing ischemically induced damage, for use as medicaments for surgical interventions for the treatment of ischemias of the nervous system, of stroke and cerebral edema, of shock, of impaired respiratory drive, for the treatment of snoring, as laxatives, as agents against ectoparasites, for the prevention of the formation of biliary calculus, as antiatherosclerotics, as agents against late diabetic complications, carcinomatous disorders, fibrotic disorders, endothelial dysfunction, and organ hypertrophies and hyperplasias. They are inhibitors of the cellular sodium/proton antiporter. They have an influence on serum lipoproteins and can therefore be used for the prophylaxis and regression of atherosclerotic changes.

  该申请公开了取代的诺博烯基氨基衍生物，其制备方法，它们作为药物或诊断工具的用途以及包含它们的药物。具有式I中的外向构型氮和内向融合的五元环，或具有式I a1中的外向构型氮和外向融合的五元环的取代诺博烯基氨基衍生物，其中R1，R2，R3，R4，R5，A，B，S1和S2如权利要求所定义，非常适用于用作降压剂，用于减少或预防缺血性损伤，用作治疗神经系统缺血，中风和脑水肿，休克，呼吸驱动力受损的手术干预药物，用于治疗打鼾，作为泻药，对抗外寄生虫药物，预防胆石形成，作为抗动脉粥样硬化药物，对抗晚期糖尿病并发症，癌症疾病，纤维病性疾病，内皮功能障碍以及器官肥大和增生。它们是细胞钠/质子抗转运体的抑制剂。它们对血清脂蛋白有影响，因此可以用于动脉粥样硬化变化的预防和回归。
• Xanthates as antitumor agents
  申请人：Merz & Co., GmbH & Co.

  公开号：US04981869A1

  公开（公告）日：1991-01-01

  Novel antitumor and antiviral xanthate compounds, a process for their production, pharmaceutical compositions containing said xanthate compounds, and a method of combating viruses and tumors therewith, are disclosed.

  本发明揭示了一种新型的抗肿瘤和抗病毒黄酸盐化合物，以及制备它们的方法，包含该黄酸盐化合物的制药组合物，以及使用该黄酸盐化合物对抗病毒和肿瘤的方法。